VA-DATAXSTREAM
23.4.2024 15:08:30 CEST | Business Wire | Press release
DataXstream LLC, an SAP solution provider focused on order management and point of sale for sales and distribution, today announced it is expanding into the Nordic region after a successful implementation of its OMS+ platform across two key business units for the Martin & Servera group, Sweden’s leading restaurant and catering distributor that specializes in the needs of the restaurant industry.
Learn more about DataXstream OMS+ here.
Martin & Servera is a group of companies based in Stockholm who was faced with the challenge of managing multiple ERP systems that were facing end of life, so they decided to consolidate onto a single instance of SAP S/4 HANA for all their business units. As part of this migration, Martin & Servera turned to DataXstream’s OMS+ cross-channel order management platform to help them enable faster order entry and streamline their sales and order processes between all companies within their organization.
Working with DataXstream’s LATAM delivery team, Kötthallen Sorunda, Sweden's leading wholesaler of meat, game, poultry and charcuterie and Fiskhallen Sorunda, the leading sustainable seafood wholesaler in Sweden, were the first two business units to successfully deploy OMS+ across their live networks. The go-live transition went exceptionally smooth, with over 500 orders created on the first day to meet the demand for the next three days.
“The complex nature of Martin & Servera’s sales and order management environment is exactly what OMS+ is built for. They are processing over 15,000 sales order lines a month and can now streamline and automate those processes in a fraction of the time, resulting in faster order entry and a better customer experience. This go-live stands out as one of the best I have ever been part of, thanks to the excellent integration, support and collaboration between Martin & Servera, the systems integrator, DataXstream and the Steering Committee,” said Diego Perelman, President, DataXstream LATAM. “Our move into the Nordic region highlights the continued need among B2B organizations to reduce complexity and streamline sales order processes within SAP SD environments.”
The OMS+ Difference
The ease of deployment across Martin & Servera’s newly installed S/4 HANA backbone is another hallmark of OMS+ as the only platform on the market today that is directly embedded into SAP as a single interface. This allows Martin & Servera to seamlessly align all their companies’ ERPs and applications onto a single platform, reducing complexity and customization, while giving them access to the same real-time master data from SAP and supporting their unique business needs.
As a result, OMS+ will equip Martin & Servera’s sales associates with:
- Real-time visibility into customer history, discounts, and product availability
- Faster manual order entry capabilities
- Access to real-time material characteristics to swiftly find the right materials for customers
- Full sales communications and tracking
Additionally, as OMS+ is embedded into SAP, it aligns perfectly with their roadmap, ensuring that new SAP functionalities are automatically available in OMS+ and the flexibility of its interface will allow Martin & Servera to adjust it easily to their unique requirements.
“We had several challenges associated with this project including an ongoing S/4 implementation that was going on in parallel to the OMS+ deployment,” said Thomas Tolvanen, IT Manager, Grönsakshallen Sorunda AB. “We are incredibly impressed by DataXstream and their professional delivery team. They have been instrumental in the S/4 process design to streamline our processes and complexity. Likewise, their deep knowledge and expertise to identify bugs and errors in customization and master data has been invaluable to us during this process. DataXstream is one of our most valuable partners.”
For additional information, please visit www.dataxstream.com or find us on the SAP store at https://store.sap.com/dcp/en/product/display-0000006561_live_v1
About Martin & Servera
The Martin & Servera group offers goods, services and knowledge for restaurants and commercial kitchens in Sweden. We are a Swedish, family-owned group. Responsible and long-term business is an important part of our business. The Martin & Servera group consists of Martin & Servera Restauranghandel, Martin & Servera Logistics, Martin & Servera Restaurant Shops, Galatea, the Vegetable Hall Sorunda, the Fish Hall Sorunda and the Meat Hall Sorunda.
About DataXstream
DataXstream is an SAP® Gold and Endorsed App Partner dedicated to building solutions on emerging technologies that maximize the ROI of our customers’ SAP® infrastructure. As members of the SAP® marketplace, DataXstream’s products can be found in the SAP® Store. Your company is already running the most powerful ERP solution; empower your employees with DataXstream’s OMS+ to take your organization’s sale and customer buying experience to new levels.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240423069303/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom